Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer‐associated venous thromboembolism
Low molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE.
No Supplementary Data
No Article Media